Zoetis Inc. (ZTS)
ZTS trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1555280/000155528026000011/0001555280-26-000011-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | ZTS on NYSE |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2013 |
| SEC CIK | 0001555280 |
| SEC industry code | Pharmaceutical Preparations |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $9.5B |
| Net income | $2.7B |
| Operating income | Not in SEC XBRL data |
| Net margin | 28.2% |
| Operating margin | Operating income not reported |
| Revenue growth | +2.3% |
| Cash | $2.5B |
| Total assets | $15.5B |
| P/E (computed) | 12.8× |
| P/S (computed) | 3.6× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-05 |
| Cash and burn | $1.3B cash; operating cash flow $682.0M a quarter. | Report 2026-09-30 |
| Shares outstanding | 406,316,147 (2026-10-30); 440,693,214 a year earlier; 459,113,691 three years earlier. | Cover page 2026-10-30 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | KPMG LLP, Short Hills, New Jersey, United States | PCAOB Form AP 2026-03-09 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $886K, sold $2.5M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $2.4B | $591.0M | $824.0M | $1.3B | $9.0B | $9.5B | 10-Q 2026-11-05 |
| Q2 2026 2026-06-30 | $2.5B | $691.0M | $655.0M | $1.5B | $9.0B | $9.5B | 10-Q 2026-08-06 |
| Q1 2026 2026-03-31 | $2.3B | $601.0M | $401.0M | $1.9B | $9.0B | $9.5B | 10-Q 2026-05-07 |
| Q4 2025 2025-12-31 | $2.4B | $624.0M | $848.0M | $2.5B | $9.0B | $9.5B | 10-K 2026-02-12 |
| Q3 2025 2025-09-30 | $2.4B | $721.0M | $936.0M | $2.1B | $7.1B | $9.4B | 10-Q 2026-11-05 |
| Q2 2025 2025-06-30 | $2.5B | $726.0M | $605.0M | $1.4B | $6.6B | $9.4B | 10-Q 2026-08-06 |
| Q1 2025 2025-03-31 | $2.2B | $602.0M | $515.0M | $1.7B | $6.6B | $9.3B | 10-Q 2026-05-07 |
| Q4 2024 2024-12-31 | $2.3B | $581.0M | $905.0M | $2.0B | $6.6B | $9.3B | 10-K 2026-02-12 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2025-08-12 |
| Latest annual report | 10-K | 2026-02-12 |
| Latest quarterly / interim | 10-Q | 2026-11-05 |
| Latest current report | 8-K | 2026-11-05 |
| Latest proxy | DEFA14A | 2026-04-08 |
Source: SEC EDGAR submissions feed, 1,004 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +5.6% |
| 1 month | +12.8% |
| 3 months | +10.5% |
| Year to date | -33.4% |
| 1 year | -30.8% |
| From 52-week high | -36.1% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| GMAB | Genmab A/S ADS | $51.57 | +0.39% | $32.2B |
| RPRX | Royalty Pharma plc Class A Ordinary Shares | $68.53 | -1.13% | $39.3B |
| ROIV | Roivant Sciences Ltd. Common Shares | $38.61 | -2.33% | $28.0B |
| INSM | Insmed Incorporated | $122.88 | +1.42% | $27.0B |
| UTHR | United Therapeutics Corporation | $587.88 | -0.56% | $25.0B |
| ONC | BeOne Medicines Ltd. | $411.29 | -1.26% | $47.0B |
| VTRS | Viatris Inc. | $20.74 | -0.38% | $23.8B |
| TEVA | Teva Pharmaceutical Industries Limited | $42.57 | -4.34% | $49.7B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier